Bausch Health is rumored to be looking to sell its Bausch + Lomb business, which will ease bankruptcy concerns and upgrade ...

Bausch + Lomb shares popped following a report that the eyecare company is considering selling itself, to separate from its ...

Bausch + Lomb Corp (NYSE:BLCO) is reportedly considering a sale as it navigates separation issues from its parent company, ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) yesterday and set a ...

Bausch Health retained an 88 per cent shareholding in the eye care subsidiary after listing the group in 2022. But it planned ...

Bausch + Lomb (BLCO) stock will be in focus as company is exploring a sale to address concerns raised over its separation ...

Bausch+Lomb, valued at over $10 billion ... with nearly 60% coming from contact lenses and eye drugs. The potential sale is part of efforts to address concerns from creditors like Apollo Global ...

Investors who lost patience in Bausch Health (BHC) at below $6.00 this past summer missed out. Last week, rumors circulated that Bausch & Lomb (BLCO) is considering a buyout. Lenders have concerns ...

Company operates a contact lens manufacturing facility in Waterford where approximately 1,500 people are employed.

In a report released yesterday, Larry Biegelsen from Wells Fargo assigned a Buy rating on Bausch + Lomb Corporation (BLCO – Research ...

Bausch+Lomb ($BLCO), a contact lens supplier, is exploring a sale to address concerns raised by its lenders like Apollo ...